Growth momentum Teknova is experiencing revenue growth with Q2 2026 hitting record levels and guidance raised for the full year, signaling expanding demand for bioprocessing and life sciences reagents that sales teams can leverage to target expanding biopharma and biotech customers.

Custom manufacturing The company highlights fully customizable solutions across RUO to GMP and a modular, scalable manufacturing platform, presenting cross-sell opportunities for customers needing tailored reagents, buffers, and packaging formats such as single-use bag filling and Fill-Tek dispensing capabilities.

AI powered tooling Launch of Build-Tek AI powered custom order configurator indicates a push toward faster, more efficient product customization, a potential selling point for customers seeking accelerated timelines and reduced development risk.

Expansion readiness Recent press mentions of expanding custom manufacturing capacity and flexible dispensing systems suggest Teknova is positioned to scale with growing demand from cell and gene therapy, diagnostics, and synthetic biology segments, creating upsell and upsell-within-portfolio opportunities.

Strategic positioning Teknova’s focus on foundational reagents for discovery and commercialization aligns with large addressable markets and similar firms with higher growth expectations, offering a pathway to strategic partnerships, co-development, or enterprise procurement deals with mid-to-large biotech customers.